Torrey Grant commutes four hours to his Syracuse University teaching job.
Torrey Grant
Torrey Grant commutes eight hours each week for a teaching job at Syracuse University.
That job is in addition to his account executive role at a PR agency where he works full time.
The share of supercommutes in the 10 largest US cities has grown from four years ago.
Torrey Grant said his roughly eight-hour weekly commute for his part-time gig is worth the timebecause he enjoys the job and it supplements his income.
In June 2022, Grant and his wife moved from Syracuse, New Yorkto New York City so they could be closer to her family. Grant landed a Manhattan-based account executive role at a public relations agency that specializes in the food, wine, and spirits industries. He was also ableto retain his part-time gig of more than five years: teaching a wine and beer appreciation course at Syracuse University, his alma mater.
During typical weeks when school is in session, he wakes up at 4:30 a.m. on Tuesdays in his Manhattan residence, drives roughly four hours to Syracuse, and is at his desk by 9 a.m. During the day, he works remotely for hispublic relations job. He then teaches two courses in the evening, stays overnight at a hotel, works remotely for his PR job the next day, teaches two more classes in the evening, and then drives home Wednesday evening.
"It's well worth it to keep a great job and it keeps my wife and I close to her family," said Grant, 50, when referring to his teaching position.
Grant is among the supercommuters who are defined by traveling more than 75 miles to work. The share of supercommutes in the 10 largest US cities was 32% greater between November 2023 and February 2024 than between the same time period four years prior, per a study from Stanford University that was published in June.
The researchers said this increase was likely driven by the uptick in remote working arrangements. For example, some Americans who moved away from their offices — in part for lower housing costs — decided they could stomach a long commute when their employers rolled out return-to-office policies after the pandemic.
Driving several hours is worth it for the job and pay
Grant said he earns between $80,000 and $100,000 annually from teaching, depending on the number of courses he teaches —which can vary based on student interest, among other factors.Grant estimated that he dedicates about 30 hours a week to his teaching job, which includes 12 hours of lecturing and additional time spent in meetings, conducting office hours, preparing for classes, and grading.
Grant said that his round-trip commuting costs typically include between $40 and $50 for a full tank of gas, roughly $80 for one night at a hotel, about $25 in tolls, and $36 to park at the school — a total of about $200 per round-trip.
Before he committed to driving as his preferred mode of transportation, Grant said he tried taking the train and flying. However, he said the train can take up to six hours if there are delays, and that flying — which can also come with delays — typically doesn't save any time.
Looking ahead, Grant said he plans to keep supercommuting for the foreseeable future. He said the biggest downside of the commute is that he has to be away from his wife two days a week. However, he said he enjoys teaching and that working with students helps him stay up to date on what's popular with younger wine and beer consumers — which can also give him a leg up at his public relations job. He said he's considered looking for teaching jobs closer to home, but only a few schools offer similar courses.
Ultimately, he said the teaching job's pay — and the limited travel costs — are what's made his commute sustainable. In the future, he said the job could bring about another financial benefit: discounted college tuition for his children.
"Financially it still makes sense," he said of the commute. "I'd love to say I would do it even if it wasn't but that's not realistic."
Do you have a long commute to work? Are you willing to share your story with a reporter? Reach out to [email protected].
Jessica DeBenedetto has only been on compounded tirzepatide for a couple of weeks, but she already feels like it's a life-changer. Her doctor prescribed the cheaper, generic version of the weight-loss drug after her insurer refused to cover Zepbound, the brand-name version made by Eli Lilly. DeBenedetto, now 43, tells me she's been prediabetic since her 20s, and after going through hormone injections with IVF, she's put on a worrying amount of weight she just can't take off. As we talk, she marvels that she's had a box of chocolates on her desk all day that she still hasn't touched, which is probably the result of both the drug and a psychological shift, since she hasn't been taking the injections that long. Still, the optimism is palpable. Those chocolates would "normally be gone in an hour," she says.
DeBenedetto's excitement has been stunted, however, by recent developments that will make compounded tirzepatide no longer widely available. The FDA has removed the drug from its shortage list and set a timeline for pharmacies to stop making compounded versions of the drug — meaning the only version available will be the FDA-approved, pricier type. She feels like the rug has been pulled out from under her.
"I'm so devastated that this option is going away," she says.
For now, her doctor is going to switch her over to compounded semaglutide — the active pharmaceutical ingredient in Ozempic and Wegovy, made by Novo Nordisk. The problem is, that's a temporary fix, too. While semaglutide is still on the shortage list, the FDA is expected to eventually end that designation, and compounders will have to stop making it, too. Lots of people could be in DeBenedetto's situation: The perfect candidate for a miracle drug whose miracle will no longer be easily accessible.
GLP-1 drugs such as semaglutide and tirzepatide are at the center of a weight-loss drug revolution. The biggest development in weight-loss medicine since bariatric surgery (not to mention less invasive), the medications, which were initially approved to treat type 2 diabetes, have exploded in popularity in recent years. People say the drugs help them drop pounds by cutting the "food noise" — making them feel fuller longer and quieting their appetites. Recent research suggests these drugs could help treat a variety of other conditions, from sleep apnea to heavy drinking.
The drugs became so popular so fast that manufacturers began running out, and patients scrambled to find Ozempic or Wegovy (the brand-name versions of semaglutide) and Monjauro or Zepbound (tirzepatide). There were other barriers to access: The brand-name versions of the drugs are expensive, in most cases costing thousands of dollars a year without insurance, and insurers have been hesitant to cover them. Moreover, not everyone who wants to lose weight has a clinical need to — a doctor saying no to a prescription doesn't always quell the desire to get one.
Some of these access issues were alleviated when the FDA put the drugs on its shortage list in 2022. This allowed compounding pharmacies to get into the GLP-1 game by creating their own versions of the injectible drugs using active ingredients obtained from chemical wholesalers and manufacturers that they could dispense when prescribed by a provider. Even though the FDA warned patients about the potential dangers of getting non-FDA-approved, compounded GLP-1s, the cat was out of the bag. Compounding pharmacies and telehealth companies saw an enormous opportunity to meet the demand for these copycat medications and offer them at a lower price point. Eli Lilly and Novo Nordisk, obviously, didn't love the setup, but there wasn't much they could do to stop it, given the shortages.
The thing about shortages is that they don't last forever. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the name-brand version, find another drug, or stop taking anything altogether. The party is over — or at least it's supposed to be.
"We all knew when semaglutide went into shortage and then when tirzepatide went into shortage that this was not a permanent status. Eventually, those drugs would be available in quantities sufficient enough to meet demand," said Scott Brunner, the CEO of the Alliance for Pharmacy Compounding, an industry group. Since October, when the FDA first determined the shortage was resolved, they've been warning members that "the end was near," he said.
Compounders aren't eager to pack it in. The Outsourcing Facilities Association, another industry group that represents compounders that produce large batches of medications, has sued to overturn the FDA's decision. Eli Lilly has since joined the FDA as a defendant to try to make sure the shortage stays resolved — it wants people taking and paying for its Monjauro and Zepbound, not cheaper copies.
You're going to have a lot of very disappointed people.
In a statement to Business Insider, an Eli Lilly spokesperson said the FDA has "correctly determined" that tirzepatide is not in shortage and that it was "clear that compounders must immediately begin transitioning patients taking compounded tirzepatide knockoffs to FDA-approved tirzepatide medicines," adding that the company will "vigorously defend" the FDA's decision. The spokesperson said the best way to ensure patients get tirzepatide is for "employers, insurers, and the government to recognize that obesity is a chronic disease and to increase coverage of medicines to treat it."
The OFA did not respond to a request for comment on this story. The APC has not joined the suit in defense of the compounders, but Brunner expressed concerns that Eli Lilly's brief had gone too far, and if the court agrees, it could end compounding by smaller pharmacies of common drugs, such as lidocaine or amoxicillin, if they were to happen to fall into a shortage for one reason or another.
The bigger picture is that there's a lot of money on the line when it comes to GLP-1s, and the parties involved know it. Compounders have found a big revenue stream they don't want to easily give up. At the same time, Eli Lilly and Novo Nordisk have market exclusivity — meaning no generics are allowed — for a limited amount of time and they want to make as much money as they can before it runs out.
For patients, this all adds up to a lot of confusion, changes, and, potentially, interruptions in treatment. The transition period will not be seamless.
"You're going to have a lot of very disappointed people," said Melanie Jay, the director of the NYU Langone Comprehensive Program on Obesity.
Many providers have begun to switch patients from tirzepatide to semaglutide or, when they can afford it, to the brand-name drug. The telehealth company Ro, which in the past offered compounded tirzepatide, in December announced it would be offering single-dose vials of Zepbound to patients with obesity. (It comes at a lower price point than the medication when delivered in an injection pen.) "We'll follow the FDA's guidance on compounding, and we'll work to ensure our patients have the best treatment options available," a Ro spokesperson said in an email.
Some compounders and telehealth companies may try to find workarounds and loopholes, especially once semaglutide is no longer in shortage. John Hertig, an associate professor at Butler University's College of Pharmacy and Health Sciences, explained that much of this depends on what's determined to be "essentially" a copy of the GLP-1 in question, meaning it's too close to see it as anything other than a duplicate. Compounders can make patient-specific (and prescription-specific) versions of medications if, for example, a person is allergic to a dye in the FDA-approved version or has trouble swallowing something in pill form. But they're only allowed to make "essential" copies in very specific circumstances — say, a drug shortage.
"There is a space in this world where compounders are important when things go on shortage or if there's a supply chain issue or you need a patient-specific alteration of a medicine because of that patient's condition," Hertig said. The problem, he added, comes when compounders are "playing games" and "skirting that essential copy regulation" by adding a minor ingredient to make the drug technically different or changing its form of delivery.
The question now becomes what counts as too close a copy to be allowed and whether a small alteration is really different — some entities might try to add vitamin B12 to their drugs or deliver it in oral form and argue that it's OK. This could very well become battleground territory.
GLP-1s are a golden goose no one wants to give up, and investors know it. When the FDA took tirzepatide off of its shortage list in December, the stock price of Hims & Hers fell amid concerns about the telehealth company's GLP-1 business. In January, Citi downgraded its rating on the stock based on the assumption that semaglutide would be off the shortage list within the next year. Hims & Hers has not offered compounded tirzepatide in the past, a spokesperson for the company said, but it does offer compounded semaglutide.
The spokesperson said it's heard from patients who are "unable to access branded GLP-1 medications" and that over half of its customers couldn't access GLP-1s they were prescribed because of its price. They added that compounders serve a "critical purpose" and pointed to part of the Federal Food, Drug, and Cosmetic Act that "permits the compounding of medications to address patients' clinical needs irrespective of whether a particular drug is subject to a shortage." When I asked whether that meant they would keep compounding semaglutide, the response was vague. It indicated that, at the very least, they're going to keep trying but in a way that's "personalized" for patients, though it's unclear how they'll achieve that for thousands of individuals.
"Many patients benefit from the standardized dose of GLP-1s, and right now, in this current shortage, we are committed to unlocking access to these life-changing medications," the spokesperson said. "With that, many patients can benefit from something different than the standardized dose, they need something more personalized, and this is an option that we make available on our platform and plan to do that for the long term."
A spokesperson for the FDA said the agency recommends patients use FDA-approved drugs when available and that compounded drugs should "only be used to fulfill the needs of patients whose medical needs cannot be met by an FDA-approved drug." The agency also warned that compounded drugs pose a higher risk to patients.
To further complicate things, the new presidential administration means new leadership at the Department of Health and Human Services and the FDA, and Donald Trump has picked Ozempic-skeptic Robert F. Kennedy Jr. to head the health department. In January, Hims & Hers donated $1 million to Trump's inauguration fund.
In the short term, this is going to be a mess. The spigot is turning off for patients on compounded tirzepatide, and compounded semaglutide's days are numbered, too. Some providers will try to find workarounds, but it's not clear how successful they'll be — or how successful regulators will be in stopping them. Patients can access the brand-name drugs, but insurance coverage and affordability remain problems. Once more reputable compounders leave the market, people might resort to sketchier operations, which could lead them to scammers, counterfeiters, and unsafe concoctions.
On the flip side, this could also be a moment for a reset. It could lead to the healthcare industry taking a better approach to GLP-1 access and care.
"Up to 70% of people with obesity who start these meds are not on it at one year anyway," Jay said. "There's a lot of reasons why people go off of it. Certainly insurance and costs, but also because I don't think people really know what they're getting into or don't have the support to really stay on them, or they think that somehow once they lose weight, they can go off of them, which is not true."
"The real thing is expensive" is not a valid reason for copying, as much as many patients wish that was the case.
"If you're Eli Lilly, you're also looking at, how do we work with patient access?" Hertig said. "How do we work with insurers? How do we manage the cost here where we're then incentivizing more patients to go to the manufacturer, which is FDA-approved? My hope would be that the manufacturers are also looking at that patient access."
Generic versions of Ozempic and Monjauro won't be available until their patents expire. What happens with compounding is unclear, but once these drugs are no longer in shortage, compounders are supposed to stop making them, except under very specific circumstances. Within that framework, "the real thing is expensive" is not a valid reason for copying, as much as many patients wish that was the case.
It's impossible to untangle exactly who's to blame here, to the extent any one party is at fault. It's the result of how the American health system is set up. Brand-name GLP-1s are much cheaper in many other parts of the world than in the US, and the drugmakers could slash their prices, but the profit motive dictates that if they don't have to, they won't. Compounding pharmacies have been filling in a legitimate gap, though some have overstepped — it's quite easy to get GLP-1s from many providers without much of an examination. Both the big guys and little guys are pushing these drugs onto consumers through ads on television and online. Of course, people are clamoring for drugs that will improve their health, help them lose weight, and reduce the stigma around their weight.
DeBenedetto said it's "ridiculous" that the government would take compounded tirzepatide away from her, even though the government is just doing what's outlined in the law. But like many other people, she didn't realize that. For the most part, the drug makers and marketers have papered over the fact that while the medications are ubiquitous, they're not widely available at a price point patients can easily afford.
"It's always about money," DeBenedetto said. "Everything's always about money, and it sucks."
Emily Stewart is a senior correspondent at Business Insider, writing about business and the economy.
President Donald Trump's tariff plans could impact the price of medicine.
Anna Moneymaker/Getty Images
Trump's first day in office on January 20 included proposed tariffs on Canada and Mexico.
Trump's tariff plans could raise the costs of some medications for Americans.
Additionally, Trump said on the campaign trail he would impose a 60% tariff on Chinese imports.
Tariffs are already a central feature ofPresident Donald Trump's second-term agenda — and those could have a significant impact on what Americans pay for some medications.
In his inauguration speeches and Day One executive orders, the president detailed his plans for imposing sweeping tariffs on foreign goods, including a 25% tariff on Mexico and Canada. Trump said the tariff policies could begin on February 1. It follows his tariff proposals from the campaign trail, including a 60% tariff on imports from China.
Some trade policy experts previously told Business Insider that broad tariffs on key trading partners like Mexico and Canada could increase the prices of goods imported from those countries. This could also stretch to key medical drugs like pain relievers, antibiotics, and cancer treatments, several of which are used in the US and manufactured abroad.
Countries like China, Canada, and Mexico not only make prescription and over-the-counter medicines, but they also supply drug ingredients. In many cases, foreign-manufactured medications are more affordable than those directly made in America — but prices and access could change with tariffs.
Trump has previously denied that his tariff policies will increase prices for Americans.Trump's press team did not immediately respond to a request for comment from BI.
What tariffs mean for your medicine costs
Under Trump's tariff plans, frequently used medications could become more expensive. Per the nonprofit organization KFF, importing some pharmaceutical drugs or ingredients from other countries has made some medicines more affordable in the US than if they were manufactured domestically due to lower production costs and cheaper labor.
In 2023, Mexico exported 165 of the 350 pharmaceutical products and drug ingredients designated as critical by the International Trade Administration. Although it was a small share of America's total pharmaceutical imports — about 1.5%, perthe nonpartisan policy research firm Wilson Center — Mexico supplied key ingredients for medicines like pain relievers and antibiotics. Major pharmaceutical and vaccine companies like Pfizer and AstraZeneca also have operations in Mexico.
Canada, too, manufactures some generic forms of over-the-counter and prescription medications, like pain relievers. Per the Census Bureau, the US imported about $5.8 billion in pharmaceutical preparations in 2023.
Some states, like Florida, have previously proposed importing some prescriptions from Canada to increase affordability. The FDA signed off on imports from Canada to Florida on a range of drugs, including those used to treat HIV, AIDS, and diabetes, and other states are working to get approval to import drugs from Canada in bulk to lower high prices.
Trump proposed even steeper tariffs on China, which could affect drug prices. A 2023 report by the policy analysis firm Atlantic Council found that, between 2020 and 2022, US imports of Chinese pharmaceuticals grew by over $8 billion, and China remains one of America's major medical suppliers. China manufactures many healthcare products used by Americans like pain relievers, cardiovascular medicine, cancer treatments and immunosuppressives, cold and cough medicine, antibiotics, and bandages.
Tariffs and trade restrictions on foreign pharmaceuticals could also lead to higher prices and drug shortages if the US is unable to manufacture cheaper alternatives. Trump has suggested enforcing a "universal tariff" on all imported goods, which may impact other main suppliers of medicine, like Ireland, Germany, Switzerland, and India.
Details are unclear on how exactly Trump will impose these tariffs, and the legal authority he uses would likely determine how soon the US could see the prices of goods change. Still, tariffs are not the only avenue through which Americans' healthcare could be impacted. On Monday, Trump signed a range of executive orders — some related to healthcare — including plans to pursue actions that will "eliminate unnecessary administrative expenses and rent-seeking practices" that raise healthcare costs.
Are you changing how you approach healthcare costs with to the new Trump administration? If so, reach out to [email protected] and [email protected].
Regeneration.VC is taking over the management of Sky Ocean Ventures' climate portfolio.
The US-headquartered fund now counts nearly 50 companies in its global portfolio.
Regeneration.VC is also expanding in Europe amid US policy shifts, adding a new partner.
Climate tech fund Regeneration.VC, which is backed by Leonardo DiCaprio as a limited partner, has taken over the management of Sky Ocean Ventures' climate portfolio.
Launched in 2022, Regeneration.VC bills itself as a consumer climate fund backing companies that are making industries such as food, apparel, and electronics more sustainable, partner Jamie Rowles told Business Insider in an interview.
Its portfolio includes the likes of recycling startup Greyparrot and textile dyeing company Colorifix.
Sky Ocean Ventures, the impact investing arm of British telecoms company Sky, had backed early-stage climate and cleantech startups working on everything from recycling technology to combatting the plastic pollution crisis. Regeneration.VC will take over the management of these companies, but Sky will still retain a financial stake in them.
Regeneration.VC now counts nearly 50 companies in its global portfolio.
"We are backing these consumer companies because those categories of climate have received less funding than energy and mobility," said Rowles. "And we're seeing a really exciting trend of some of the world's biggest corporates wanting to make changes in their value chains and their supply chains."
Trump 2.0 is spurring climate funds to invest in Europe
Along with the expansion of its portfolio, Regeneration.VC is adding a new partner to its European office. Narina Mnatsakanian, who was UBS' former head of impact investment, will also be the fund's new chief impact officer. In 2023, Regeneration's founding partner, Michael Smith, moved to the Netherlands.
Rowles also joined the firm in November 2024 in a bid to double down on its presence in the UK, and raise capital from limited partners for its second $150 million fund.
Europe is fast becoming an attractive hotspot for climate VCs amid a change in the US administration. Trump has been vocal in his support for oil and gas initiatives and has threatened to push back on the Inflation Reduction Act, which facilitated investment in clean energy. A potential shift in climate policy has encouraged some climate tech investors to look to Europe for more investment opportunities, Rowles said.
In the past year, US-based climate tech funds such as Voyager Ventures and Energy Impact Partners have also grown their European footprint with new appointments on the continent.
"The concept of sustainable and impact investment will have better tailwinds in Europe for the next few years," Rowles told BI. "Can sustainable investing survive Trump 2.0? For us, it's strategic to have a European presence, even though the DNA of the firm is the US. We have to be aligned with EU systems."
Regeneration.VC will still be investing in the US because of its "great pools of capital and risk appetite," — but Rowles emphasized that being aligned with the European Union on climate was a huge priority for the fund.
"We will see more climate tech funds with more of a presence in Europe," he said. "The reality is, you need to be in both markets to do the type of work we're doing. But in Europe, there's better regulation and better mechanisms to avoid greenwashing," he added.
A four-day exercise being held in South Korea involves South Korean FA-50 fighter aircraft and KA-1 attack aircraft, as well as U.S. A-10 attack aircraft.
President Donald Trump's swearing-in ceremony Monday featured the largest, most complex security footprint of any inauguration in U.S. history.
The nation's capital was transformed seemingly overnight from a pedestrian-friendly city into a daunting and impenetrable fortress – the result of a multi-agency task force that erected 30 miles of anti-scale fencing, coordinated aerial surveillance and drones, and saw the deployment of tens of thousands of law enforcement, military personnel, undercover agents, and national guard trucks across D.C.
The impressive, whole-of-government security effort on Inauguration Day was unprecedented, and not without reason: Trump was the victim of two assassination attempts during the 2024 campaign — including a shooter who came so close to him as to nick his ear — and a domestic threat landscape that was heightened further by the terrorist-inspired attack in New Orleans and the execution-style killing of United Healthcare CEO Brian Thompson in Midtown Manhattan late last year.
It's notable, then, that this year’s sprawling security footprint did not expressly include one key component considered fundamental to U.S. tradition: The naming of a designated survivor.
In D.C., the tightly coordinated federal protection efforts were carefully planned long ahead of Trump's inauguration ceremony by the Secret Service and many other federal agencies.
It's both a nod to recent security concerns, and more largely an effort to protect the U.S. body politic, foreign dignitaries, donors, and thousands of attendees from any mass catastrophe or threat.
The designated survivor, who in a catastrophic event would bear the responsibility of leading the U.S. in the aftermath of a crisis, is typically a Cabinet officer when major security events put elected officials all in one spot, such as inaugurations and State of the Union addresses.
Previous designated survivors have included former DHS secretary Jeh Johnson, former Energy Secretary Rick Perry, and former Defense Secretary Robert Gates, who was tapped for the role during President Barack Obama's inauguration in 2009.
Gates, a George W. Bush appointee, was kept on by Obama and served in his Pentagon role until July 2011, according to his official Defense Department biography.
The survivor's location, and sometimes identity, remains confidential until after the event disperses and its attendees have safely returned home. In high-profile events, a broader contingency plan is in place.
As Garrett Graff reported in 2016, Gates's role as designated survivor during Obama's inauguration also included the support of another government heavyweight — James Clapper, then the undersecretary of intelligence — who stowed away during the ceremony deep in an underground government bunker in Pennsylvania, a backup to the backup, if you will, and a nod at the detailed succession plan carefully crafted by a group defense, intelligence, and other federal agencies over the span of some 40-plus years.
So it was notable that no designated survivor was named during the 47th presidential inauguration.
It's also possible the event, which was held indoors and thus restricted to the public and to members of the news media, was limited enough as not to warrant the designated survivor.
Ahead of the event, FBI and Secret Service personnel stressed the stringent security measures in place and the tight vetting of any ticketed attendees.
David Sundberg of the FBI's Washington Field Office told Fox News earlier this week that the bureau was not tracking "any specific or credible threats" for Inauguration Day.
"All attendees will undergo screening," said Matt McCool, special agent in charge of the Secret Service's Washington Field Office.
These individuals told Fox News that the fencing alone is more than any other designated National Special Security Event in the past.
"Designated checkpoints will be set up for members of the public interested in attending the inauguration," McCool said ahead of the inauguration — a protocol also applied to attendees of the modified Capital One festivities, which were moved inside due to frigid temperatures.
Neither the White House, DHS nor the FBI immediately responded to Fox News Digital's request for comment on the absence of a designated survivor.
Fox News Digital's Elizabeth Elkind contributed to this report.
A reported rising star in the Democratic Party, who is being recruited to run for office in Texas, has a social media footprint littered with racially charged posts as well as numerous crude comments about President Trump.
Accomplished singer and songwriter Bobby Pulido is being "heavily recruited," according to a recent Politico report, to run as a Democrat in Texas’ 15th Congressional District and Pulido himself has said that he intends to put his singing career on hold to run for political office in 2026.
Pulido’s social media presence is littered with examples of racially charged posts along with vulgar posts about President-elect Trump which are likely to be used against him if he decides to run for Congress.
"How convenient that Wikileaks only hacked the democrat party," Pulido said in a reply to the GOP Asian American account on X, then known as Twitter, in 2016. "Open your Asian eyes. That's more rigged than anything."
Numerous examples of Pulido using crude language to attack Trump can be found on his page, which would presumably be unpopular with Republican voters in Texas, a state he won by 14 points in November while making historically significant strides with Hispanic voters in the Lone Star State.
In 2015, a Twitter user asked Pulido in Spanish, "What would you say to people who bully me because I listen to your music?"
It is unclear what specific political race Pulido is planning on entering, but he has made it clear he intends to launch his candidacy in the near future and Politico reported he would likely be considered to run in Texas' 15th Congressional District against Republican Rep. Monica De La Cruz.
"Growing up I was always intrigued by the idea of public service," Pulido said in a recent livestream discussing retiring from music. "In 2026 I’ll be running for public office in the attempt to fulfill my lifelong dream to serve my people."
Fox News Digital reached out to Pulido, but he did not respond to a request for comment.
Philadelphia roots are apparently thicker than blood in the Kelce household ... 'cause Fletcher Cox tells TMZ Sports he's sure Jason Kelce would cheer for the Eagles to beat Travis Kelce's Chiefs if they met in next month's Super Bowl. A Philly…
